Overview
Olaparib is an oral targeted therapy belonging to the PARP inhibitor class. It blocks enzymes involved in DNA repair, particularly in cancer cells with BRCA1/BRCA2 mutations and certain other DNA repair deficiencies. It is used in selected treatment settings for ovarian, breast, pancreatic and prostate cancers.